Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Dozens of witnesses oppose House Bill 324, raising scientific, legal and access concerns
Summary
House Bill 324 would direct the Ohio Department of Health to identify drugs with severe adverse effects occurring in more than 5% of users based on insurance claims, patient reports and FDA data. Multiple clinicians, researchers, pharmacies, advocacy groups and students opposed the bill at the committee hearing, arguing the statutorily prescribed
House Bill 324, which would require the Ohio Director of Health to identify medicines that cause specified severe adverse events in more than 5 percent of users based on a set of data sources, drew extensive testimony and opposition at its third hearing before the House Health Committee.
Dr. Lisonbee Norris, an epidemiologist and reproductive health researcher, testified as an interested‑party witness that the bill’s required evidence sources — insurance claims, patient reports to health care professionals, and applicable FDA data — could lead the Department of Health to rely on poorly conducted analyses. She told the committee that one report often cited by proponents (Hall and Anderson) counts emergency department visits and routine follow‑up care as "serious adverse events,"…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
